Mometasone: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #272 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Corticosteroids]] | |||
[[Category:Glucocorticoids]] | |||
[[Category:Inhaled corticosteroids]] | |||
Latest revision as of 10:43, 23 May 2026
Mometasone furoate
Nasonex (intranasal), Asmanex (inhaled), Elocon (topical), Sinuva (sinus implant); with formoterol as Dulera
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Pharmacy
Starting dose
Intranasal Nasonex 2 sprays/nostril daily (50 mcg/spray); inhaled Asmanex 220 mcg DPI 1-2 inhalations daily/BID; topical Elocon 0.1% cream daily
Preparations
Nasonex 50 mcg/actuation intranasal; Asmanex HFA MDI 100/200 mcg; Asmanex Twisthaler DPI 110/220 mcg; Elocon 0.1% cream/ointment/lotion; Sinuva sinus implant; Dulera (with formoterol)
US FDA Max
Intranasal 200 mcg/d (adults); inhaled 880 mcg/d
Common uses
Classification(s)
Pharmacology
Routes
Intranasal, inhaled, topical, intranasal sinus implant
Onset
Intranasal: symptom relief 12-24 hours; inhaled: bronchial effect 1-2 weeks
Duration
24 hours
Half-life
~5 hours (plasma)[1]
Bioavailability
Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance[1]
Pregnancy
Intranasal long considered acceptable; widely used in obstetric rhinitis.[citation needed]
Legal status
OTC (Nasonex 24HR) and Rx-only (other forms) in US
Purported mechanism
Mometasone furoate is a high-affinity glucocorticoid receptor agonist with extensive hepatic first-pass clearance (CYP3A4) that minimizes systemic glucocorticoid exposure from inhaled, intranasal, or topical administration.0 Like other locally-acting corticosteroids, broadly suppresses inflammatory gene transcription; clinical onset is gradual for asthma controller use but rapid for allergic rhinitis. Once-daily intranasal dosing reflects strong receptor binding and slow tissue clearance[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Nasonex (mometasone furoate), Organon/Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020762s048lbl.pdf